- Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer
-
Tate S, Nishikimi , Kato K, Matsuoka A, Kambe M, Kiyokawa T, Shozu M
- KMID: 2500482
- J Gynecol Oncol.
- 2020 Apr;31(3):e34.
- doi: 10.3802/jgo.2020.31.e34
Objective: This study aimed to evaluate the presence of pathological residual tumor (pRT) in each initial disseminated site after neoadjuvant chemotherapy (NACT) to assess the appropriate surgical margins during interval... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
-
Jang JY, Yanaihara , Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann , Shimada M, Kiyokawa T, Kim BG, Matsumura , Kaku T, Kuroda T, Nagayoshi , Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A
- KMID: 2413437
- J Gynecol Oncol.
- 2017 Jul;28(4):e54.
- doi: 10.3802/jgo.2017.28.e54
There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update... -
- CITED
-
- Close
- SHARE
-
- Close
